Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation.

Derosa L, Bayar MA, Albiges L, Le Teuff G, Escudier B.

Angiogenesis. 2019 Feb 9. doi: 10.1007/s10456-019-09664-2. [Epub ahead of print]

PMID:
30739258
2.

Les métastases cérébrales de cancer du rein, un défi clinique.

Flippot R, Derosa L, Albiges L.

Bull Cancer. 2018 Dec;105 Suppl 3:S261-S267. doi: 10.1016/S0007-4551(18)30381-3. Review. French.

PMID:
30595155
3.

Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre.

Ruatta F, Derosa L, Escudier B, Colomba E, Guida A, Baciarello G, Loriot Y, Fizazi K, Albiges L.

Eur J Cancer. 2019 Jan;107:79-85. doi: 10.1016/j.ejca.2018.10.023. Epub 2018 Dec 11.

PMID:
30551078
4.

The intimate relationship between gut microbiota and cancer immunotherapy.

Elkrief A, Derosa L, Zitvogel L, Kroemer G, Routy B.

Gut Microbes. 2019;10(3):424-428. doi: 10.1080/19490976.2018.1527167. Epub 2018 Oct 19.

5.

[In bacteria veritas: pronostic role of intestinal microbiote in cancer therapy].

Messaoudene M, Derosa L, Belkaid W, Routy B.

Med Sci (Paris). 2018 Aug-Sep;34(8-9):657-659. doi: 10.1051/medsci/20183408009. Epub 2018 Sep 19. French. No abstract available.

PMID:
30230457
6.

The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1.

Derosa L, Routy B, Kroemer G, Zitvogel L.

Oncoimmunology. 2018 Apr 18;7(6):e1434468. doi: 10.1080/2162402X.2018.1434468. eCollection 2018.

7.

The impact of the intestinal microbiota in therapeutic responses against cancer.

Goubet AG, Daillère R, Routy B, Derosa L, M Roberti P, Zitvogel L.

C R Biol. 2018 May - Jun;341(5):284-289. doi: 10.1016/j.crvi.2018.03.004. Epub 2018 Apr 7. Review.

8.

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.

Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, Rouche JA, Zitvogel L, Zalcman G, Albiges L, Escudier B, Routy B.

Ann Oncol. 2018 Jun 1;29(6):1437-1444. doi: 10.1093/annonc/mdy103.

9.

Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors.

Mittal K, Derosa L, Albiges L, Wood L, Elson P, Gilligan T, Garcia J, Dreicer R, Escudier B, Rini B.

Clin Genitourin Cancer. 2018 Jun;16(3):e663-e667. doi: 10.1016/j.clgc.2017.12.014. Epub 2018 Jan 4.

PMID:
29428404
10.

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L.

Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.

PMID:
29097494
11.

Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy.

Guida A, Albiges L, Derosa L, Loriot Y, Massard C, Fizazi K, Escudier B.

Clin Genitourin Cancer. 2017 Dec;15(6):e1081-e1088. doi: 10.1016/j.clgc.2017.07.015. Epub 2017 Aug 12.

PMID:
28888866
12.

Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680-7.

Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini C, Miccoli M, Galli L, Falcone A, Jenster GW, van Schaik RH, Danesi R.

Eur Urol. 2018 Jan;73(1):e11-e12. doi: 10.1016/j.eururo.2017.07.034. Epub 2017 Aug 9. No abstract available.

PMID:
28801127
13.

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.

Colomba E, Le Teuff G, Eisen T, Stewart GD, Fife K, Larkin J, Biondo A, Pickering L, Srinivasan A, Boyle H, Derosa L, Sternberg CN, Recine F, Ralph C, Saldana C, Barthélémy P, Bernhard JC, Gurney H, Verhoest G, Vauleon E, Bigot P, Berger J, Pfister C, Gravis G, Rodier JM, Culine S, Caty A, Rolland F, Priou F, Escudier B, Albiges L.

Eur J Cancer. 2017 Jul;80:55-62. doi: 10.1016/j.ejca.2017.03.011. Epub 2017 May 23.

PMID:
28549248
14.

The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide.

Del Re M, Fogli S, Derosa L, Massari F, De Souza P, Crucitta S, Bracarda S, Santini D, Danesi R.

Cancer Treat Rev. 2017 Apr;55:71-82. doi: 10.1016/j.ctrv.2017.03.001. Epub 2017 Mar 9. Review.

PMID:
28340451
15.

Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents.

Grassi P, Doucet L, Giglione P, Grünwald V, Melichar B, Galli L, De Giorgi U, Sabbatini R, Ortega C, Santoni M, Bamias A, Verzoni E, Derosa L, Studentova H, Porcu L, De Braud F, Porta C, Procopio G.

Oncology. 2017;92(5):269-275. doi: 10.1159/000455970. Epub 2017 Feb 17.

PMID:
28208153
16.

Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma.

Derosa L, Izzedine H, Albiges L, Escudier B.

Oncol Rev. 2016 Nov 24;10(2):298. eCollection 2016 Oct 10. Review.

17.

Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.

Verzoni E, De Giorgi U, Derosa L, Caffo O, Boccardo F, Facchini G, Porcu L, De Vincenzo F, Zaniboni A, Chiuri VE, Fratino L, Santini D, Adamo V, De Vivo R, Dinota A, Messina C, Ricotta R, Caserta C, Scavelli C, Susi M, Tartarone A, Surace G, Mosca A, Bruno M, Barni S, Grassi P, Procopio G.

Oncotarget. 2016 Jun 28;7(26):40085-40094. doi: 10.18632/oncotarget.9485.

18.

The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.

Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini C, Miccoli M, Galli L, Falcone A, Jenster GW, van Schaik RH, Danesi R.

Eur Urol. 2017 Apr;71(4):680-687. doi: 10.1016/j.eururo.2016.08.012. Epub 2016 Oct 10.

PMID:
27733296
19.

Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients.

Di Desidero T, Derosa L, Galli L, Orlandi P, Fontana A, Fioravanti A, Marconcini R, Giorgi M, Campi B, Saba A, Lucchesi S, Felipetto R, Danesi R, Francia G, Allegrini G, Falcone A, Bocci G.

Invest New Drugs. 2016 Dec;34(6):760-770. Epub 2016 Aug 24.

PMID:
27557783
20.

Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer.

Conteduca V, Crabb SJ, Jones RJ, Caffo O, Elliott T, Scarpi E, Fabbri P, Derosa L, Massari F, Numico G, Zarif S, Hanna C, Maines F, Joyce H, Lolli C, De Giorgi U.

PLoS One. 2016 Jul 19;11(7):e0158952. doi: 10.1371/journal.pone.0158952. eCollection 2016.

21.

Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.

Lolli C, Basso U, Derosa L, Scarpi E, Sava T, Santoni M, Crabb SJ, Massari F, Aieta M, Conteduca V, Maruzzo M, La Russa F, Wheater M, Berardi R, Galli L, De Giorgi U.

Oncotarget. 2016 Aug 23;7(34):54564-54571. doi: 10.18632/oncotarget.10515.

22.

Long-Term PSA Control with Repeated Stereotactic Body Radiotherapy in a Patient with Oligometastatic Castration-Resistant Prostate Cancer.

Pasqualetti F, Cocuzza P, Coraggio G, Ferrazza P, Derosa L, Galli L, Pasqualetti G, Locantore L, Boni R, Fabrini MG, Erba PA.

Oncol Res Treat. 2016;39(4):217-20. doi: 10.1159/000444906. Epub 2016 Mar 30.

PMID:
27160394
23.

Safety of available treatment options for renal cell carcinoma.

Derosa L, Albiges L, Massard C, Loriot Y, Fizazi K, Escudier B.

Expert Opin Drug Saf. 2016 Aug;15(8):1097-106. doi: 10.1080/14740338.2016.1184643. Epub 2016 May 23. Review.

PMID:
27142582
24.

Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis.

Grassi P, Doucet L, Giglione P, Grünwald V, Melichar B, Galli L, De Giorgi U, Sabbatini R, Ortega C, Santoni M, Bamias A, Verzoni E, Derosa L, Studentova H, Pacifici M, Coppa J, Mazzaferro V, de Braud F, Porta C, Escudier B, Procopio G.

PLoS One. 2016 Apr 11;11(4):e0151662. doi: 10.1371/journal.pone.0151662. eCollection 2016.

25.

Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer.

Conteduca V, Crabb SJ, Scarpi E, Hanna C, Maines F, Joyce H, Fabbri P, Derosa L, Massari F, Lolli C, Zarif S, Jones RJ, Caffo O, Elliott T, De Giorgi U.

Mol Diagn Ther. 2016 Jun;20(3):255-63. doi: 10.1007/s40291-016-0196-1.

PMID:
27020582
26.

[(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results.

Pasqualetti F, Panichi M, Sainato A, Matteucci F, Galli L, Cocuzza P, Ferrazza P, Coraggio G, Pasqualetti G, Derosa L, Sollini M, Mannelli L, Ortori S, Monzani F, Ricci S, Greco C, Fabrini MG, Erba PA.

Radiat Oncol. 2016 Jan 22;11:9. doi: 10.1186/s13014-016-0586-x.

27.

Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.

Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B; Rainbow Group.

Ann Oncol. 2016 Feb;27(2):366. doi: 10.1093/annonc/mdv589. Epub 2015 Dec 18. No abstract available.

PMID:
26685011
28.

Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era.

Gravis G, Chanez B, Derosa L, Beuselinck B, Barthelemy P, Laguerre B, Brachet PE, Joly F, Escudier B, Harrison DJ, Laird A, Vasudev N, Ralph C, Larkin J, Lote H, Salem N, Walz J, Thomassin J, Sfumato P, Stewart GD, Boher JM; Renal Cross Channel Group.

Urol Oncol. 2016 Apr;34(4):167.e17-23. doi: 10.1016/j.urolonc.2015.10.015. Epub 2015 Dec 3.

PMID:
26670200
29.

Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation.

Bracarda S, Caserta C, Galli L, Carlini P, Pastina I, Sisani M, Scali S, Hamzaj A, Derosa L, Felici A, Rossi M, Altavilla A, Chioni A, De Angelis V.

Future Oncol. 2015 Nov;11(22):3083-90. doi: 10.2217/fon.15.217. Epub 2015 Oct 5.

PMID:
26437324
30.

Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients.

Solini A, Simeon V, Derosa L, Orlandi P, Rossi C, Fontana A, Galli L, Di Desidero T, Fioravanti A, Lucchesi S, Coltelli L, Ginocchi L, Allegrini G, Danesi R, Falcone A, Bocci G.

Oncotarget. 2015 Oct 6;6(30):28743-54. doi: 10.18632/oncotarget.4926.

31.

Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.

Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B; Rainbow Group.

Ann Oncol. 2015 Oct;26(10):2107-13. doi: 10.1093/annonc/mdv315. Epub 2015 Jul 27. Erratum in: Ann Oncol. 2016 Feb;27(2):366.

PMID:
26216384
32.

Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone.

Conteduca V, Caffo O, Derosa L, Veccia A, Petracci E, Chiuri VE, Santoni M, Santini D, Fratino L, Maines F, Testoni S, De Giorgi U.

Prostate. 2015 Sep;75(12):1329-38. doi: 10.1002/pros.23014. Epub 2015 May 15.

PMID:
25982919
33.

Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma.

Izzedine H, Derosa L, Le Teuff G, Albiges L, Escudier B.

Ann Oncol. 2015 Jun;26(6):1128-33. doi: 10.1093/annonc/mdv147. Epub 2015 Mar 20.

PMID:
25795198
34.

Small-bowel neuroendocrine tumor and retroperitoneal fibrosis: efficacy of octreotide and tamoxifen.

Biasco E, Antonuzzo A, Galli L, Baldi GG, Derosa L, Marconcini R, Farnesi A, Ricci S, Falcone A.

Tumori. 2015 Mar 20;101(1):e24-8. doi: 10.5301/tj.5000259.

PMID:
25702678
35.

Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.

Santoni M, Buti S, Conti A, Porta C, Procopio G, Sternberg CN, Bracarda S, Basso U, De Giorgi U, Rizzo M, Derosa L, Ortega C, Massari F, Milella M, Bersanelli M, Cerbone L, Muzzonigro G, Burattini L, Montironi R, Santini D, Cascinu S.

Target Oncol. 2015 Dec;10(4):517-22. doi: 10.1007/s11523-014-0356-3. Epub 2015 Jan 6.

PMID:
25559290
36.

Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center.

Izzedine H, Escudier B, Lhomme C, Pautier P, Rouvier P, Gueutin V, Baumelou A, Derosa L, Bahleda R, Hollebecque A, Sahali D, Soria JC.

Medicine (Baltimore). 2014 Nov;93(24):333-9. doi: 10.1097/MD.0000000000000207. Erratum in: Medicine (Baltimore). 2014 Nov;93(24):414.

37.

Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.

Santoni M, Conti A, Partelli S, Porta C, Sternberg CN, Procopio G, Bracarda S, Basso U, De Giorgi U, Derosa L, Rizzo M, Ortega C, Massari F, Iacovelli R, Milella M, Di Lorenzo G, Buti S, Cerbone L, Burattini L, Montironi R, Santini D, Falconi M, Cascinu S.

Ann Surg Oncol. 2015;22(6):2094-100. doi: 10.1245/s10434-014-4256-7. Epub 2014 Dec 4.

PMID:
25472645
38.

Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.

Derosa L, Galli L, Orlandi P, Fioravanti A, Di Desidero T, Fontana A, Antonuzzo A, Biasco E, Farnesi A, Marconcini R, Francia G, Danesi R, Falcone A, Bocci G.

Cancer. 2014 Dec 15;120(24):3923-31. doi: 10.1002/cncr.28953. Epub 2014 Aug 8.

39.

Early and prolonged response to pazopanib in a patient with multiple metastases from renal cell carcinoma: a case report.

Biasco E, Antonuzzo A, Cianci C, Derosa L, Marconcini R, Farnesi A, Galli L.

Tumori. 2014 May-Jun;100(3):e83-6. doi: 10.1700/1578.17240.

PMID:
25076257
40.

Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.

Santoni M, Conti A, Porta C, Procopio G, Sternberg CN, Basso U, De Giorgi U, Bracarda S, Rizzo M, Ortega C, Massari F, Iacovelli R, Derosa L, Masini C, Milella M, Di Lorenzo G, Atzori F, Pagano M, Buti S, De Vivo R, Mosca A, Rossi M, Paglino C, Verzoni E, Cerbone L, Muzzonigro G, Falconi M, Montironi R, Burattini L, Santini D, Cascinu S.

J Urol. 2015 Jan;193(1):41-7. doi: 10.1016/j.juro.2014.07.011. Epub 2014 Jul 18.

PMID:
25046616
41.

Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.

Procopio G, Derosa L, Gernone A, Morelli F, Sava T, Zustovich F, De Giorgi U, Ferrari V, Sabbatini R, Gasparro D, Felici A, Burattini L, Calvani N, Lo Re G, Banna G, Pia Brizzi M, Rizzo M, Ciuffreda L, Iacovelli R, Ferraù F, Taibi E, Bracarda S, Porta C, Galligioni E, Contu A.

Future Oncol. 2014 Aug;10(10):1741-50. doi: 10.2217/fon.14.48. Epub 2014 Mar 18.

42.

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide.

Orlandi P, Fontana A, Fioravanti A, Di Desidero T, Galli L, Derosa L, Canu B, Marconcini R, Biasco E, Solini A, Francia G, Danesi R, Falcone A, Bocci G.

Br J Cancer. 2013 Aug 20;109(4):957-64. doi: 10.1038/bjc.2013.398. Epub 2013 Jul 16.

43.

Metronomic chemotherapy for metastatic prostate cancer: a 'young' concept for old patients?

Fontana A, Falcone A, Derosa L, Di Desidero T, Danesi R, Bocci G.

Drugs Aging. 2010 Sep 1;27(9):689-96. doi: 10.2165/11537480-000000000-00000. Review.

PMID:
20809660
44.

Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer.

Fontana A, Bocci G, Galli L, D'Arcangelo M, Derosa L, Fioravanti A, Orlandi P, Barletta MT, Landi L, Bursi S, Minuti G, Bona E, Grazzini I, Danesi R, Falcone A.

J Am Geriatr Soc. 2010 May;58(5):986-8. doi: 10.1111/j.1532-5415.2010.02833.x. No abstract available.

PMID:
20722827
45.

Point-of-care monitoring of oral anticoagulation therapy in children. Comparison of the CoaguChek XS system with venous INR and venous INR using an International Reference Thromboplastin preparation (rTF/95).

Greenway A, Ignjatovic V, Summerhayes R, Newall F, Burgess J, DeRosa L, Monagle P.

Thromb Haemost. 2009 Jul;102(1):159-65. doi: 10.1160/TH09-01-0056.

PMID:
19572081
46.

Screening for consumptive coagulopathy in preeclampsia.

Metz J, Cincotta R, Francis M, DeRosa L, Balloch A.

Int J Gynaecol Obstet. 1994 Jul;46(1):3-9.

PMID:
7805980
47.
48.

A case of glaucoma detection without findings of high pressures.

DeRosa LU.

J Am Optom Assoc. 1980 Oct;51(10):945-6. No abstract available.

PMID:
7451799
49.

HAEMOGLOBIN CASERTA: AN ABNORMAL HAEMOGLOBIN OBSERVED IN A SOUTHERN ITALIAN FAMILY.

VENTRUTO V, BAGLIONI C, DEROSA L, BIANCHI P, COLOMBO B, QUATTRIN N.

Scand J Haematol. 1965;2:118-25. No abstract available.

PMID:
14343423
50.

[ON THE PELGER-HUEET ANOMALY: A CASE OF PARTIAL CARRIER].

DEROSA L, DINI E, CUOMO A.

Haematologica. 1965;50:153-61. Italian. No abstract available.

PMID:
14330704

Supplemental Content

Loading ...
Support Center